杭州天目山药业股份有限公司 2025 年第三次临时股东大会会议资料 杭州天目山药业股份有限公司 2025 年第三次临时股东大会 会议资料 中国•杭州 二〇二五年九月十二日 1 / 8 杭州天目山药业股份有限公司 2025 年第三次临时股东大会会议资料 目 录 | 2025 年第三次临时股东大会会议议程 | 3 | | --- | --- | | 2025 年第三次临时股东大会须知 | 4 | | 议案一：关于取消监事会并修订《公司章程》的议案 | 5 | | 议案二：关于取消监事会并废止《监事会议事规则》的议案 | 7 | | 议案三：关于修订、制定部分公司治理制度的议案 | 8 | 2 / 8 杭州天目山药业股份有限公司 2025 年第三次临时股东大会会议资料 2025年第三次临时股东大会会议议程 会议召开方式：本次股东大会采用现场会议和网络投票相结合的方式，网络投票 系统为上海证券交易所股东大会网络投票系统 会议召集人：董事会 会议主持人：公司董事长 会议议程： 3 / 8 现场会议时间：2025年9月12日下午14:00 现场会议地点：浙江省杭州市博亚时代中心1803会议室 一、大会主持人介绍到会股东及 ...

证券日报网讯 9月2日晚间，天目药业发布公告称，公司聘任韩同旻先生担任公司副总经理。 （文章来源：证券日报） ...

Group 1 - Tianmu Pharmaceutical announced the resignation of Wang Yihui from the positions of director, member of the strategic committee, and financial director due to work relocation [1] - The company appointed Han Tongmin as the new deputy general manager and Dang Guojun as the new financial director, effective from the date of board approval until the end of the current board term [1] - Huang Junde was elected as a member of the compensation and assessment committee, also until the end of the current board term [1] Group 2 - For the fiscal year 2024, Tianmu Pharmaceutical's revenue composition is as follows: health products 31.37%, pharmaceutical circulation products 21.97%, service category 19.74%, raw materials 12.64%, and traditional Chinese medicine 11.84% [1] - As of the report date, Tianmu Pharmaceutical has a market capitalization of 2.3 billion yuan [1]

Core Viewpoint - Tianmu Pharmaceutical announced the approval of multiple proposals, including the appointment of a new vice president, during the 15th meeting of its 12th board of directors [2] Group 1 - The company held its 15th meeting of the 12th board of directors on September 2 [2] - The board approved the proposal regarding the appointment of a vice president [2]

Core Viewpoint - The announcement details the resignation of Wang Yihui, the company's director and CFO, due to job relocation, and the subsequent appointments of new senior management personnel and adjustments to the board's specialized committees [1][2]. Group 1: Resignation of Senior Management - Wang Yihui submitted her resignation as a director, strategic committee member, and CFO, effective immediately upon delivery to the board [1][2]. - Her resignation will not affect the board's minimum number of members or the company's daily operations, and she has no outstanding commitments or obligations to the company [2]. Group 2: Appointment of New Senior Management - The company appointed Han Tongmin as the new vice president and Dang Guojun as the new CFO, effective from the date of the board's approval [1][2][3]. - Both new appointees have no prior stock holdings in the company and meet all legal and regulatory requirements for their positions [5][6]. Group 3: Adjustment of Board Committees - The board approved the adjustment of its specialized committees, electing non-independent director Huang Junde as a member of the Compensation and Assessment Committee [4]. - The current members of the Compensation and Assessment Committee are Pei Yang (Chairman), Sheng Xiaomeng, and Huang Junde [4].

Group 1 - The company held its 15th meeting of the 12th Board of Directors on September 1, 2025, with all 8 directors present, complying with legal and regulatory requirements [1][2] - The Board approved the appointment of Mr. Han Tongmin as the Vice General Manager, with a term lasting until the end of the current Board's tenure [1][2] - The Board also approved the appointment of Mr. Dang Guojun as the Chief Financial Officer, with a similar term duration [2][3] Group 2 - The Board made adjustments to the members of the Compensation and Assessment Committee, electing non-independent director Mr. Huang Junde as a member [2][3] - The voting results for all resolutions were unanimous, with 8 votes in favor and no votes against or abstentions [2][3]

Group 1 - The core viewpoint of the article is that Tianmu Pharmaceutical (SH 600671) held its 15th meeting of the 12th board of directors on September 1, 2025, to discuss the appointment of a new financial director and other documents [1] - For the fiscal year 2024, the revenue composition of Tianmu Pharmaceutical is as follows: health products account for 31.37%, pharmaceutical circulation products account for 21.97%, service-related products account for 19.74%, raw materials account for 12.64%, and traditional Chinese medicine accounts for 11.84% [1] - As of the time of reporting, the market capitalization of Tianmu Pharmaceutical is 2.3 billion yuan [1]

证券代码：600671 证券简称：天目药业 编号：临 2025-039 | 姓名 | 离任职务 | 离任时间 | 原定任期 | 离任原因 | 是否继续在上 市公司及其控 | 具体职务 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 到期日 | | 股子公司任职 | （如适用） | 毕的公开 | | | | | | | | | 承诺 | | | 董事、战 | | | | | | | | | 略委员会 | | | | | | | | | | 2025 年 8 | 2027 年 6 | | | | | | 王一惠 | 委员和财 | | | 工作调动 | 否 | | 否 | | | | 月 29 日 | 月 12 日 | | | | | | | 务总监职 | | | | | | | | | 务 | | | | | | | 杭州天目山药业股份有限公司 关于董事兼高级管理人员辞职、调整董事会专门委员 会委员及聘任高级管理人员的公告 （一）提前离任的基本情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或 ...

证券代码：600671 证券简称：天目药业 公告编号：临 2025-038 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 杭州天目山药业股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日以现 场结合通讯表决方式召开了第十二届董事会第十五次会议。本次会议通知及会议 材料于 2025 年 8 月 29 日以电子或书面的方式送达各位董事。本次会议应出席董 事 8 名，实际出席董事 8 名。会议由董事长刘加勇先生主持，公司部分高级管理 人员列席会议。本次会议的召开符合《公司法》和《公司章程》的有关规定。本 次会议审议情况如下： 二、董事会会议审议情况 经与会董事表决，会议审议并通过了如下决议： （一）审议并通过《关于聘任公司副总经理的议案》 经公司总经理提名，董事会同意聘任韩同旻先生为公司副总经理，任期至公 司第十二届董事会届满为止。 本议案经董事会提名委员会审议通过。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《关 于董事兼高级管理人员辞职、调整董事会专门委 ...

Market Overview - The Chinese traditional medicine sector saw a slight increase of 0.32% on August 29, with Darentang leading the gains [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Top Performers - Darentang (600329) closed at 46.11, with a rise of 4.80% and a trading volume of 167,100 shares, amounting to a transaction value of 765 million [1] - Enwei Pharmaceutical (301331) increased by 2.22% to close at 35.94, with a trading volume of 15,900 shares [1] - Jianmin Group (600976) rose by 2.19% to 42.43, with a transaction value of 208 million [1] Underperformers - Qidi Pharmaceutical (000590) decreased by 3.11% to 11.84, with a trading volume of 129,400 shares and a transaction value of 155 million [2] - Tianmu Pharmaceutical (600671) fell by 2.89% to 19.81, with a transaction value of 209 million [2] - Buchang Pharmaceutical (603858) saw a decline of 2.55% to 19.51, with a trading volume of 198,400 shares [2] Capital Flow - The traditional medicine sector experienced a net outflow of 510 million from institutional investors, while retail investors saw a net inflow of 469 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Darentang had a net inflow of 77.24 million from institutional investors, but a net outflow of 59.46 million from retail investors [3] - Yunnan Baiyao (000538) saw a net inflow of 55.91 million from institutional investors, while retail investors had a net outflow of 0.83 million [3] - Zhendong Pharmaceutical (300158) experienced a net inflow of 48.61 million from institutional investors, but a significant net outflow of 79.17 million from retail investors [3]